MicroRNA MIR-93-5p regulates expression of IL-8 and VEGF in neuroblastoma SK-N-AS cells

Oncology Reports

Volumn 35, Issue 5, 2016, Pages 2866-2872

  Fabbri, Enrica ^a   Montagner, Giulia ^a   Bianchi, Nicoletta ^a   Finotti, Alessia ^a   Borgatti, Monica ^a   Lampronti, Ilaria ^a   Cabrini, Giulio ^b   Gambari, Roberto ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY HOSPITAL OF FERRARA   (Italy)

Author keywords

Interleukin 8; MicroRNA; Neuroblastoma; Vascular endothelial growth factor

Indexed keywords

CHEMOKINE; CYTOKINE; GROWTH FACTOR; INTERLEUKIN 8; MICRORNA; MICRORNA 93 5P; UNCLASSIFIED DRUG; VASCULOTROPIN; 3' UNTRANSLATED REGION; IL8 PROTEIN, HUMAN; MIRN93 MICRORNA, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ARTICLE; CONTROLLED STUDY; CYTOKINE RESPONSE; GENE FUNCTION; IN VITRO STUDY; NEUROBLASTOMA CELL LINE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN RNA BINDING; PROTEIN SECRETION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; BINDING SITE; CONFORMATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; INVERTED REPEAT; METABOLISM; NEUROBLASTOMA; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; BASE SEQUENCE; BINDING SITES; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-8; INVERTED REPEAT SEQUENCES; MICRORNAS; NEUROBLASTOMA; NUCLEIC ACID CONFORMATION; RNA INTERFERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84964022132     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2016.4676     Document Type: Article

References (44)

1. Park JR, Bagatell R, London WB, Maris JM, Cohn SL, Mattay KK, Hogarty M; COG Neuroblastoma Committee: Children's Oncology Group's 2013 blueprint for research: Neuroblastoma. Pediatr Blood Cancer 60: 985-993, 2013.
2. Ribatti D, Marimpietri D, Pastorino F, Brignole C, Nico B, Vacca A and Ponzoni M: Angiogenesis in neuroblastoma. Ann NY Acad Sci 1028: 133-142, 2004.
3. Ribatti D: Anti-angiogenesis in neuroblastoma. Crit Rev Oncol Hematol 86: 212-221, 2013.
4. Eggert A, Ikegaki N, Kwiatkowski J, Zhao H, Brodeur GM and Himelstein BP: High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin Cancer Res 6: 1900-1908, 2000.
5. Choudhury SR, Karmakar S, Banik NL and Ray SK: Targeting angiogenesis for controlling neuroblastoma. J Oncol 2012: 782020, 2012.
6. Shusterman S and Maris JM: Prospects for therapeutic inhibition of neuroblastoma angiogenesis. Cancer Lett 228: 171-179, 2005.
7. Megison ML, Gillory LA and Beierle EA: Cell survival signaling in neuroblastoma. Anticancer Agents Med Chem 13: 563-575, 2013.
8. Pistoia V, Bianchi G, Borgonovo G and Raffaghello L: Cytokines in neuroblastoma: From pathogenesis to treatment. Immunotherapy 3: 895-907, 2011.
9. Neuschäfer-Rube F, Pathe-Neuschäfer-Rube A, Hippenstiel S, Kracht M and Püschel GP: NF-κB-dependent IL-8 induction by prostaglandin E2 receptors EP1 and EP4. Br J Pharmacol 168: 704-717, 2013.
10. Finotti A, Borgatti M, Bezzerri V, Nicolis E, Lampronti I, Dechecchi M, Mancini I, Cabrini G, Saviano M, Avitabile C, et al: Effects of decoy molecules targeting NF-kappaB transcription factors in cystic fibrosis IB3-1 cells: Recruitment of NF-kappaB to the IL-8 gene promoter and transcription of the IL-8 gene. Artif DNA PNA XNA 3: 97-296, 2012.
11. Khanjani S, Terzidou V, Johnson MR, Bennett PR: NFκB and AP-1 drive human myometrial IL8 expression. Mediators Inflamm 2012: 504952, 2012.
12. Bezzerri V, Borgatti M, Finotti A, Tamanini A, Gambari R and Cabrini G: Mapping the transcriptional machinery of the IL-8 gene in human bronchial epithelial cells. J Immunol 187: 6069-6081, 2011.
13. Wei T, Xu N, Meisgen F, Stahle M, Sonkoly E and Pivarcsi A: Interleukin-8 is regulated by MIR-203 at the posttranscriptional level in primary human keratinocytes. Eur J Dermatol: Apr 19, 2013 (Epub ahead of print).
14. Perng DW, Yang DM, Hsiao YH, Lo T, Lee OK, Wu MT, Wu YC and Lee YC: miRNA-146a expression positively regulates tumor necrosis factor-α-induced interleukin-8 production in mesenchymal stem cells and differentiated lung epithelial-like cells. Tissue Eng Part A 18: 2259-2267, 2012.
15. Chuang TD, Luo X, Panda H and Chegini N: MIR-93/106b and their host gene, MCM7, are differentially expressed in leiomyomas and functionally target F3 and IL-8. Mol Endocrinol 26: 1028-1042, 2012.
16. Zhou R, Li X, Hu G, Gong AY, Drescher KM and Chen XM: MIR-16 targets transcriptional corepressor SMRT and modulates NF-kappaB-regulated transactivation of interleukin-8 gene. PLoS One 7: e30772, 2012.
17. Bhattacharyya S, Balakathiresan NS, Dalgard C, Gutti U, Armistead D, Jozwik C, Srivastava M, Pollard HB and Biswas R: Elevated MIR-155 promotes inflammation in cystic fibrosis by driving hyperexpression of interleukin-8. J Biol Chem 286: 11604-11615, 2011.
18. Bhaumik D, Scott GK, Schokrpur S, Patil CK, Orjalo AV, Rodier F, Lithgow GJ and Campisi J: MicroRNAs MIR-146a/b negatively modulate the senescence-associated inflammatory mediators IL-6 and IL-8. Aging 1: 402-411, 2009.
19. Khan FH, Pandian V, Ramraj S, Aravindan S, Herman TS and Aravindan N: Reorganization of metastamiRs in the evolution of metastatic aggressive neuroblastoma cells. BMC Genomics 16: 501, 2015.
20. Chen L, Li ZY, Xu SY, Zhang XJ, Zhang Y, Luo K and Li WP: Upregulation of MIR-107 inhibits glioma angiogenesis and VEGF expression. Cell Mol Neurobiol: Jun 18, 2015 (Epub ahead of print).
21. Tsuchiya M, Kumar P, Bhattacharyya S, Chattoraj S, Srivastava M, Pollard HB and Biswas R: Differential regulation of inflammation by inflammatory mediators in cystic fibrosis lung epithelial cells. J Interferon Cytokine Res 33: 121-129, 2013.
22. Cabrini G, Fabbri E, Lo Nigro C, Dechecchi MC and Gambari R: Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review). Int J Oncol 47: 417-428, 2015.
23. Bianchi N, Finotti A, Ferracin M, Lampronti I, Zuccato C, Breveglieri G, Brognara E, Fabbri E, Borgatti M, Negrini M, et al: Increase of microRNA-210, decrease of raptor gene expression and alteration of mammalian target of rapamycin regulated proteins following mithramycin treatment of human erythroid cells. PLoS One 10: e0121567, 2015.
24. Sun K and Lai EC: Adult-specific functions of animal microRNAs. Nat Rev Genet 14: 535-548, 2013.
25. Berindan-Neagoe I, Monroig PC, Pasculli B and Calin GA: MicroRNAome genome: A treasure for cancer diagnosis and therapy. CA Cancer J Clin 64: 311-336, 2014.
26. Adams BD, Kasinski AL and Slack FJ: Aberrant regulation and function of microRNAs in cancer. Curr Biol 24: R762-R776, 2014.
27. Hayes J, Peruzzi PP and Lawler S: MicroRNAs in cancer: Biomarkers, functions and therapy. Trends Mol Med 20: 460-469, 2014.
28. Piva R, Spandidos DA and Gambari R: From microRNA functions to microRNA therapeutics: Novel targets and novel drugs in breast cancer research and treatment (Review). Int J Oncol 43: 985-994, 2013.
29. Fabbri E, Borgatti M, Montagner G, Bianchi N, Finotti A, Lampronti I, Bezzerri V, Dechecchi MC, Cabrini G and Gambari R: Expression of microRNA-93 and interleukin-8 during Pseudomonas aeruginosa-mediated induction of proinflammatory responses. Am J Respir Cell Mol Biol 50: 1144-1155, 2014.
30. Long J, Wang Y, Wang W, Chang BH and Danesh FR: Identification of microRNA-93 as a novel regulator of vascular endothelial growth factor in hyperglycemic conditions. J Biol Chem 285: 23457-23465, 2010.
31. Fang L, Deng Z, Shatseva T, Yang J, Peng C, Du WW, Yee AJ, Ang LC, He C, Shan SW, et al: MicroRNA MIR-93 promotes tumor growth and angiogenesis by targeting integrin-β8. Oncogene 30: 806-821, 2011.
32. Sugimoto T, Tatsumi E, Kemshead JT, Helson L, Green AA and Minowada J: Determination of cell surface membrane antigens common to both human neuroblastoma and leukemia-lymphoma cell lines by a panel of 38 monoclonal antibodies. J Natl Cancer Inst 73: 51-57, 1984.
33. Borgatti M, Mancini I, Bianchi N, Guerrini A, Lampronti I, Rossi D, Sacchetti G and Gambari R: Bergamot (Citrus bergamia Risso) fruit extracts and identified components alter expression of interleukin 8 gene in cystic fibrosis bronchial epithelial cell lines. BMC Biochem 12: 15, 2011.
34. Penolazzi L, Lambertini E, Tavanti E, Torreggiani E, Vesce F, Gambari R and Piva R: Evaluation of chemokine and cytokine profiles in osteoblast progenitors from umbilical cord blood stem cells by BIO-PLEX technology. Cell Biol Int 32: 320-325, 2008.
35. Brognara E, Fabbri E, Bazzoli E, Montagner G, Ghimenton C, Eccher A, Cantù C, Manicardi A, Bianchi N, Finotti A, et al: Uptake by human glioma cell lines and biological effects of a peptide-nucleic acids targeting MIR-221. J Neurooncol 118: 19-28, 2014.
36. Hofacker IL: Vienna RNA secondary structure server. Nucleic Acids Res 31: 3429-3431, 2003.
37. Kent WJ, Hsu F, Karolchik D, Kuhn RM, Clawson H, Trumbower H and Haussler D: Exploring relationships and mining data with the UCSC Gene Sorter. Genome Res 15: 737-741, 2005.
38. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A and Enright AJ: miRBase: MicroRNA sequences, targets and gene nomenclature. Nucleic Acids Res 34: D140-D144, 2006.
39. Kozomara A and Griffiths-Jones S: miRBase: Annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res 42: D68-D73, 2014.
40. Betel D, Wilson M, Gabow A, Marks DS and Sander C: The microRNA.org resource: Targets and expression. Nucleic Acids Res 36 (Database): D149-D153, 2008.
41. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP and Burge CB: Prediction of mammalian microRNA targets. Cell 115: 787-798, 2003.
42. Dweep H, Gretz N and Sticht C: miRWalk database for miRNAtarget interactions. Methods Mol Biol 1182: 289-305, 2014.
43. Fabbri E, Manicardi A, Tedeschi T, Sforza S, Bianchi N, Brognara E, Finotti A, Breveglieri G, Borgatti M, Corradini R, et al: Modulation of the biological activity of microRNA-210 with peptide nucleic acids (PNAs). ChemMedChem 6: 2192-2202, 2011.
44. Gambari R, Fabbri E, Borgatti M, Lampronti I, Finotti A, Brognara E, Bianchi N, Manicardi A, Marchelli R and Corradini R: Targeting microRNAs involved in human diseases: A novel approach for modification of gene expression and drug development. Biochem Pharmacol 82: 1416-1429, 2011.